Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases
Shots:
- ShapeTX will receive an initial fee and is eligible to receive ~$1.5B in development, regulatory, and sales milestones along with royalties on future sales of products that resulted from the collaboration
- The collaboration will combine ShapeTX’s AAVid capsid discovery platform and transgene engineering technology with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for serious eye diseases
- Additionally, ShapeTX will also apply transgene engineering technology to optimize payloads provided by Otsuka for therapeutic levels of gene expression in targeted cell types
Ref: Globenewswire | Image: Otsuka
Related News:- Roche Collaborated with Avista to Develop AAV Gene Therapy Vectors for the Treatment of Ocular Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
